Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006-2008)

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 3, 2010, Pages 329-331

  Sader, Helio S ^a   Becker, Holly K ^a   Moet, Gary J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

HVISA; MRSA; Vancomycin heteroresistance; Vancomycin tolerance

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; EUROPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; CROSS INFECTION; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES; VANCOMYCIN;

EID: 77349108597     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.09.017     Document Type: Article

References (15)

1. Boucher H.W., Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 2007, 45:601-608.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, M07-A8 2009, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19) 2009, CLSI, Wayne, PA.
4. Cubicin Package Insert Available at, Accessed on June 2009. http://www.cubicin.com/pdf/PrescribingInformation.pdf.
5. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50:1079-1082.
6. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2009, 199:605-609.
7. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., Grabsch E.A., Roberts S.A., Robson J., Read K., Bak N., Hurley J., Johnson P.D., Morris A.J., Mayall B.C., Grayson M.L. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004, 38:521-528.
8. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 2006, 42(Suppl. 1):S13-S24.
9. Leonard S.N., Rossi K.L., Newton K.L., Rybak M.J. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 2009, 63:489-492.
10. Maor Y., Hagin M., Belausov N., Keller N., Ben-David D., Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus Bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 2009, 199:619-624.
11. Moody J., Knapp C. Tests to assess bactericidal activity. Clinical microbiology procedures handbook 2004, 5.10.31-36. ASM Press, Washington, DC. H.D. Isenberg (Ed.).
12. Neoh H.M., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., Hiramatsu K. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 2007, 6:13.
13. Sader H.S., Jones R.N. Antimicrobial susceptibility of Gram-positive bacteria isolated from United States medical centers: Result of the Daptomycin Surveillance Program (2007--2008). Diagn. Microbiol. Infect. Dis. 2009, 65:158-162.
14. Sader H.S., Moet G.J., Jones R.N. Update of the In vitro activity of daptomycin tested 17,193 Gram-positive Bacteria isolated from European medical centers (2005-2007). J. Chemother. 2009, [In Press].
15. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol 2004, 42:2398-2402.